Neomatrix Therapeutics, Inc.
NeoMatrix Therapeutics is a clinical-stage company dedicated to developing novel, bioactive peptides aimed at preventing injury progression and enhancing tissue healing, particularly in severe burn cases. Founded by Dr. Richard A. Clark, the company focuses on innovative therapies that significantly improve the quality of life and clinical outcomes for burn patients.
Industries
Nr. of Employees
small (1-50)
Neomatrix Therapeutics, Inc.
25 Health Sciences Drive, Suite 124, Stony Brook, NY 11790
Patents
Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
US-11548935-B2
View DetailsMethods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
US-10729741-B2
View Details
Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
US-11548935-B2
View DetailsMethods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
US-10729741-B2
View DetailsProducts
ECM-derived 14-mer peptide for intravenous treatment of acute severe burns (Phase 2-ready)
A 14-amino-acid peptide derived from extracellular matrix protein fragments intended for IV administration within hours of burn injury to limit injury progression, improve microvascular perfusion, accelerate healing, and reduce scarring. Reported Phase 1 safety data in healthy volunteers; indicated as Phase 2-ready.
Protease-resistant peptide for topical and intravenous treatment of burns (Pre-IND / Preclinical)
A modified peptide engineered to resist exopeptidases and neutrophil elastase, developed for both topical and IV use within 8–24 hours post-injury; currently in pre-IND development for IV use and preclinical testing with multiple topical delivery vehicles.
ECM-derived 14-mer peptide for intravenous treatment of acute severe burns (Phase 2-ready)
A 14-amino-acid peptide derived from extracellular matrix protein fragments intended for IV administration within hours of burn injury to limit injury progression, improve microvascular perfusion, accelerate healing, and reduce scarring. Reported Phase 1 safety data in healthy volunteers; indicated as Phase 2-ready.
Protease-resistant peptide for topical and intravenous treatment of burns (Pre-IND / Preclinical)
A modified peptide engineered to resist exopeptidases and neutrophil elastase, developed for both topical and IV use within 8–24 hours post-injury; currently in pre-IND development for IV use and preclinical testing with multiple topical delivery vehicles.
Services
Exploration of strategic collaborations, investments, or licensing with partners to supplement capabilities for clinical advancement and commercialization.
Preclinical testing, formulation screening, and preparation of IND-enabling studies for peptide candidates intended for burn treatment.
Design and execution of early clinical studies including Phase 1 safety studies and planned Phase 2a efficacy trials in burn patients.
Exploration of strategic collaborations, investments, or licensing with partners to supplement capabilities for clinical advancement and commercialization.
Preclinical testing, formulation screening, and preparation of IND-enabling studies for peptide candidates intended for burn treatment.
Design and execution of early clinical studies including Phase 1 safety studies and planned Phase 2a efficacy trials in burn patients.
Expertise Areas
- Peptide therapeutics development
- Burn injury therapeutics
- Preclinical animal models (porcine burn model)
- In vitro cell-based assay development
Key Technologies
- Peptide therapeutic design
- Protease-resistant peptide engineering
- In vitro cell culture assays (proliferation, migration, cytoprotection)
- Porcine burn injury model